ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) have been given a consensus rating of “Moderate Buy” by the sixteen research firms that are currently covering the firm, Marketbeat reports. Five investment analysts have rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $25.56.

A number of research analysts recently commented on the company. Stifel Nicolaus decreased their price objective on ACADIA Pharmaceuticals from $26.00 to $21.00 and set a “hold” rating on the stock in a report on Thursday, May 9th. Mizuho decreased their price objective on ACADIA Pharmaceuticals from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Thursday, May 9th. StockNews.com cut ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 3rd. Bank of America decreased their price objective on ACADIA Pharmaceuticals from $26.00 to $22.00 and set a “neutral” rating on the stock in a report on Friday, May 10th. Finally, Cantor Fitzgerald decreased their price objective on ACADIA Pharmaceuticals from $37.00 to $28.00 and set an “overweight” rating on the stock in a report on Wednesday, August 7th.

Insider Transactions at ACADIA Pharmaceuticals

In other news, CEO Stephen Davis sold 31,747 shares of the company’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $15.28, for a total transaction of $485,094.16. Following the sale, the chief executive officer now owns 186,555 shares of the company’s stock, valued at $2,850,560.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CEO Stephen Davis sold 31,747 shares of the company’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $15.28, for a total transaction of $485,094.16. Following the sale, the chief executive officer now owns 186,555 shares of the company’s stock, valued at $2,850,560.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Mark C. Schneyer sold 9,733 shares of the stock in a transaction on Monday, August 19th. The shares were sold at an average price of $15.28, for a total value of $148,720.24. Following the completion of the transaction, the chief financial officer now directly owns 43,735 shares in the company, valued at approximately $668,270.80. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 51,989 shares of company stock valued at $793,914. 28.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

Several large investors have recently bought and sold shares of ACAD. Fisher Asset Management LLC purchased a new position in ACADIA Pharmaceuticals in the fourth quarter valued at $4,479,000. Natixis Advisors L.P. increased its holdings in ACADIA Pharmaceuticals by 17.6% in the fourth quarter. Natixis Advisors L.P. now owns 40,875 shares of the biopharmaceutical company’s stock valued at $1,279,000 after buying an additional 6,112 shares during the last quarter. Los Angeles Capital Management LLC increased its holdings in ACADIA Pharmaceuticals by 43.9% in the fourth quarter. Los Angeles Capital Management LLC now owns 65,179 shares of the biopharmaceutical company’s stock valued at $2,041,000 after buying an additional 19,871 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in ACADIA Pharmaceuticals by 5.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,127,907 shares of the biopharmaceutical company’s stock valued at $35,315,000 after buying an additional 54,814 shares during the last quarter. Finally, E Fund Management Co. Ltd. boosted its stake in ACADIA Pharmaceuticals by 32.4% in the fourth quarter. E Fund Management Co. Ltd. now owns 22,893 shares of the biopharmaceutical company’s stock valued at $717,000 after acquiring an additional 5,605 shares in the last quarter. Hedge funds and other institutional investors own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Price Performance

Shares of ACADIA Pharmaceuticals stock opened at $16.32 on Friday. The stock has a market cap of $2.70 billion, a P/E ratio of -1,632.00 and a beta of 0.38. The stock’s 50 day simple moving average is $16.82 and its 200-day simple moving average is $17.85. ACADIA Pharmaceuticals has a 1-year low of $14.55 and a 1-year high of $32.59.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.02. ACADIA Pharmaceuticals had a negative return on equity of 0.41% and a negative net margin of 0.21%. The business had revenue of $241.96 million for the quarter, compared to analysts’ expectations of $235.95 million. During the same period in the previous year, the firm posted $0.01 EPS. The business’s revenue for the quarter was up 46.4% compared to the same quarter last year. As a group, research analysts expect that ACADIA Pharmaceuticals will post 0.58 EPS for the current fiscal year.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.